Antibody Persistence 3 Years after Immunization of Adolescents with Quadrivalent Meningococcal Conjugate Vaccine | Zendy

David M. Vu | Zendy; Jo Anne Welsch | Zendy; Patricia ZunoMitchell | Zendy; Josefa V. Dela Cruz | Zendy; Dan M. Granoff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibody Persistence 3 Years after Immunization of Adolescents with Quadrivalent Meningococcal Conjugate Vaccine

Author(s) -

David M. Vu,

Jo Anne Welsch,

Patricia ZunoMitchell,

Josefa V. Dela Cruz,

Dan M. Granoff

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/500512

Subject(s) - medicine , vaccination , titer , persistence (discontinuity) , immunization , meningococcal vaccine , antibody , antibody titer , conjugate vaccine , immunology , bacteremia , neisseria meningitidis , immunity , microbiology and biotechnology , immune system , biology , bacteria , antibiotics , genetics , geotechnical engineering , engineering

A quadrivalent meningococcal conjugate vaccine (MCV-4) is recommended for United States teenagers. The duration of protective immunity is unknown. We investigated serum antibody persistence 3 years after vaccination of adolescents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research